AMGN up +1.45% percent right now. $AMGN High is at 163.00 and the Low 160.50 with current volume of 1,363,236.
Recent News posted below.
AMGN Amgen Inc Recent Headline News
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - 1 hr 22 mins ago
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.62 (+0.02), IMGN: 9.84 (+0.07), AMGN: 162.18 (+1.93), LLY: 67.84 (+1.24), ONTX: 4.85 (+0.07), BMY: 58.56 (+0.24), GSK: 45.17 (+0.26), OXGN: 2.01 (-0.15), XLRN: 31.69 (+1.50), KPTI: 42.44 (+0.30), NVS: 92.38 (+0.62)
Early Glance: Biotechnology companies
AP - 2 hrs 20 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 107.45 (+1.00), AMGN: 162.18 (+1.93), CELG: 107.65 (+1.20)
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 110.30 (-2.47), ABMD: 32.77 (+0.64), JNJ: 108.63 (+0.43), AMGN: 162.18 (+1.93), EXAS: 22.51 (-0.31), ARAY: 6.87 (+0.02), HOLX: 26.45 (+0.24), PBYI: 238.10 (+1.21)
FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab
PR Newswire - Mon Nov 10, 8:15AM CST
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.1
AMGN: 162.18 (+1.93)
Ziarco Raises $33.1 Million in Series B Financing
GlobeNewswire - Mon Nov 10, 6:07AM CST
Ziarco Group Ltd, a biopharmaceutical company focusing on inflammatory skin diseases, today announced the completion of a $33.1 million Series B financing round. New Enterprise Associates, Inc. (NEA) and Lundbeckfond Ventures co-led the round with new investor Amgen Ventures joining the existing investors BVF Partners L.P. and Pfizer Venture Investments. Ed Mathers, partner at NEA, has joined Ziarco's board of directors as Chairman. Johan Kordel, senior partner at Lundbeckfond Ventures, has also joined the board.
AMGN: 162.18 (+1.93)
Medical Device Companies Were Election Day Winners
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 08, 11:00AM CST
Source: Library of Congress The shift in power in Washington may have big implications for medical device companies if legislation is rekindled to ditch the 2.3% medical device tax. That tax, enacted as part of Obamacare to help fund the cost of...
BIIB: 325.08 (+4.33), MDT: 68.49 (+0.39), AMGN: 162.18 (+1.93), SYK: 88.15 (+0.68)
Final Glance: Biotechnology companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 107.45 (+1.00), AMGN: 162.18 (+1.93), CELG: 107.65 (+1.20)
Midday Glance: Biotechnology companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 107.45 (+1.00), AMGN: 162.18 (+1.93), CELG: 107.65 (+1.20)
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
PR Newswire - Fri Nov 07, 7:50AM CST
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.
HCA: 67.27 (+1.52), JNJ: 108.63 (+0.43), PCYC: 132.69 (-0.80), SHPG: 200.87 (+2.29), MRK: 58.98 (-0.36), AMGN: 162.18 (+1.93)
Amgen To Present At The Credit Suisse Annual Healthcare Conference
PR Newswire - Thu Nov 06, 3:30PM CST
Amgen (NASDAQ: AMGN) will participate at the Credit Suisse Annual Healthcare Conference on Tuesday, Nov. 11, 2014, at The Arizona Biltmore in Phoenix, beginning at 8:30 a.m. MT. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
AMGN: 162.18 (+1.93)
Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014
PR Newswire - Thu Nov 06, 3:01PM CST
Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that more than 50 abstracts from the Company's oncology and hematology portfolios have been accepted for presentation at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH) being held Dec. 6 - 9, 2014, in San Francisco.
AMGN: 162.18 (+1.93)
The Zacks Analyst Blog Highlights:AbbVie, Regeneron, Aegerion, Geron and Amgen
PR Newswire - Thu Nov 06, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie (NYSE:ABBV-Free Report), Regeneron (Nasdaq:REGN-Free Report), Aegerion (Nasdaq:AEGR-Free Report), Geron (Nasdaq:GERN-Free Report) and Amgen (Nasdaq:AMGN-Free Report).
AMGN: 162.18 (+1.93)
Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 7:36AM CST
AEGR data by YCharts What: Shares of Aegerion Pharmaceuticals , a biopharmaceutical company focused on developing drugs to treat rare diseases, collapsed in October and lost 40% of their value, based on data from S&P Capital IQ , after...
AMGN: 162.18 (+1.93), AEGR: 21.50 (-0.08)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 16.21 (+0.71), PFE: 30.20 (+0.28), AMGN: 162.18 (+1.93), AXN: 0.27 (-0.01), SRNE: 4.76 (+0.11), NKTR: 13.75 (+0.40), EGLT: 6.55 (-0.24), AZN: 73.20 (+0.32), VBAY: ()
Bone Metastasis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 31 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/t39trm/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Eli Lilly and Company - Takeda Pharmaceutical Company Limited - Sigma-Tau S.p.A. - Bayer AG - Medivir AB - Osteologix Holdings Plc. - Transgene SA - Merrion Pharmaceuticals Plc - Digna Biotech, S.L. - Debiopharm International S.A. - Amura Holdings Ltd. - Alethia Biotherapeutics Inc. - Deciphera Pharmaceuticals, LLC - Terpenoid Therapeutics, Inc. - R-Pharm - TWi Pharmaceuticals, Inc. - DexTech Medical AB - AlphaMab Co., Ltd Drug Profiles - denosumab - zoledronic acid - MLN-1202 - radium Ra 223 dichloride - Osteodex - MIV-711 - RPH-203 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Vicrostatin - ADM-01 - LY-2109761 - LY-364937 - Drugs to Inhibit EGFR for Bone Metastasis - (alendronate sodium paclitaxel PEG) - alendronate sodium HPMA paclitaxel - DCC-3014 - Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - TPH-9 - NBS-101 - Recombinant Protein to Inhibit Serine Protease for Bone Metastasis For more information visit http://www.researchandmarkets.com/research/t3...metastasis
AMGN: 162.18 (+1.93), LLY: 67.83 (+1.23)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 99.15 (+3.31), AMGN: 162.18 (+1.93), SNY: 46.29 (+0.60), REGN: 382.31 (+4.47)
Recent News posted below.
AMGN Amgen Inc Recent Headline News
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - 1 hr 22 mins ago
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.62 (+0.02), IMGN: 9.84 (+0.07), AMGN: 162.18 (+1.93), LLY: 67.84 (+1.24), ONTX: 4.85 (+0.07), BMY: 58.56 (+0.24), GSK: 45.17 (+0.26), OXGN: 2.01 (-0.15), XLRN: 31.69 (+1.50), KPTI: 42.44 (+0.30), NVS: 92.38 (+0.62)
Early Glance: Biotechnology companies
AP - 2 hrs 20 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 107.45 (+1.00), AMGN: 162.18 (+1.93), CELG: 107.65 (+1.20)
VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 110.30 (-2.47), ABMD: 32.77 (+0.64), JNJ: 108.63 (+0.43), AMGN: 162.18 (+1.93), EXAS: 22.51 (-0.31), ARAY: 6.87 (+0.02), HOLX: 26.45 (+0.24), PBYI: 238.10 (+1.21)
FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab
PR Newswire - Mon Nov 10, 8:15AM CST
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.1
AMGN: 162.18 (+1.93)
Ziarco Raises $33.1 Million in Series B Financing
GlobeNewswire - Mon Nov 10, 6:07AM CST
Ziarco Group Ltd, a biopharmaceutical company focusing on inflammatory skin diseases, today announced the completion of a $33.1 million Series B financing round. New Enterprise Associates, Inc. (NEA) and Lundbeckfond Ventures co-led the round with new investor Amgen Ventures joining the existing investors BVF Partners L.P. and Pfizer Venture Investments. Ed Mathers, partner at NEA, has joined Ziarco's board of directors as Chairman. Johan Kordel, senior partner at Lundbeckfond Ventures, has also joined the board.
AMGN: 162.18 (+1.93)
Medical Device Companies Were Election Day Winners
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 08, 11:00AM CST
Source: Library of Congress The shift in power in Washington may have big implications for medical device companies if legislation is rekindled to ditch the 2.3% medical device tax. That tax, enacted as part of Obamacare to help fund the cost of...
BIIB: 325.08 (+4.33), MDT: 68.49 (+0.39), AMGN: 162.18 (+1.93), SYK: 88.15 (+0.68)
Final Glance: Biotechnology companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 107.45 (+1.00), AMGN: 162.18 (+1.93), CELG: 107.65 (+1.20)
Midday Glance: Biotechnology companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 107.45 (+1.00), AMGN: 162.18 (+1.93), CELG: 107.65 (+1.20)
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
PR Newswire - Fri Nov 07, 7:50AM CST
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.
HCA: 67.27 (+1.52), JNJ: 108.63 (+0.43), PCYC: 132.69 (-0.80), SHPG: 200.87 (+2.29), MRK: 58.98 (-0.36), AMGN: 162.18 (+1.93)
Amgen To Present At The Credit Suisse Annual Healthcare Conference
PR Newswire - Thu Nov 06, 3:30PM CST
Amgen (NASDAQ: AMGN) will participate at the Credit Suisse Annual Healthcare Conference on Tuesday, Nov. 11, 2014, at The Arizona Biltmore in Phoenix, beginning at 8:30 a.m. MT. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
AMGN: 162.18 (+1.93)
Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014
PR Newswire - Thu Nov 06, 3:01PM CST
Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that more than 50 abstracts from the Company's oncology and hematology portfolios have been accepted for presentation at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH) being held Dec. 6 - 9, 2014, in San Francisco.
AMGN: 162.18 (+1.93)
The Zacks Analyst Blog Highlights:AbbVie, Regeneron, Aegerion, Geron and Amgen
PR Newswire - Thu Nov 06, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie (NYSE:ABBV-Free Report), Regeneron (Nasdaq:REGN-Free Report), Aegerion (Nasdaq:AEGR-Free Report), Geron (Nasdaq:GERN-Free Report) and Amgen (Nasdaq:AMGN-Free Report).
AMGN: 162.18 (+1.93)
Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 7:36AM CST
AEGR data by YCharts What: Shares of Aegerion Pharmaceuticals , a biopharmaceutical company focused on developing drugs to treat rare diseases, collapsed in October and lost 40% of their value, based on data from S&P Capital IQ , after...
AMGN: 162.18 (+1.93), AEGR: 21.50 (-0.08)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 16.21 (+0.71), PFE: 30.20 (+0.28), AMGN: 162.18 (+1.93), AXN: 0.27 (-0.01), SRNE: 4.76 (+0.11), NKTR: 13.75 (+0.40), EGLT: 6.55 (-0.24), AZN: 73.20 (+0.32), VBAY: ()
Bone Metastasis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 31 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/t39trm/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Eli Lilly and Company - Takeda Pharmaceutical Company Limited - Sigma-Tau S.p.A. - Bayer AG - Medivir AB - Osteologix Holdings Plc. - Transgene SA - Merrion Pharmaceuticals Plc - Digna Biotech, S.L. - Debiopharm International S.A. - Amura Holdings Ltd. - Alethia Biotherapeutics Inc. - Deciphera Pharmaceuticals, LLC - Terpenoid Therapeutics, Inc. - R-Pharm - TWi Pharmaceuticals, Inc. - DexTech Medical AB - AlphaMab Co., Ltd Drug Profiles - denosumab - zoledronic acid - MLN-1202 - radium Ra 223 dichloride - Osteodex - MIV-711 - RPH-203 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Vicrostatin - ADM-01 - LY-2109761 - LY-364937 - Drugs to Inhibit EGFR for Bone Metastasis - (alendronate sodium paclitaxel PEG) - alendronate sodium HPMA paclitaxel - DCC-3014 - Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - TPH-9 - NBS-101 - Recombinant Protein to Inhibit Serine Protease for Bone Metastasis For more information visit http://www.researchandmarkets.com/research/t3...metastasis
AMGN: 162.18 (+1.93), LLY: 67.83 (+1.23)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 99.15 (+3.31), AMGN: 162.18 (+1.93), SNY: 46.29 (+0.60), REGN: 382.31 (+4.47)
